New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced ...

Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica ...

studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed ...

Imagine stepping into a space where cutting-edge technology meets life-changing impact. At Novartis we’re building something extraordinary – an Innovation Lab (iLab) where we are mastering the art and ...

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...

February 19, 2026 – Novartis AG has notified the Board of Novartis India Limited (“NIL”), a company listed on BSE Limited, that Novartis AG has entered into an agreement with the ChrysCapital group ...

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...